Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter.

Fourteen patients with previously treated, locally advanced/metastatic transitional cell carcinoma (TCC) of the bladder or ureter received paclitaxel at a dose of 200 mg m-2 administered as a 3-h infusion every 21 days. The activity of paclitaxel in this group of patients was modest. The response ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Papamichael, D., Gallagher, C. J., Oliver, R. T., Johnson, P. W., Waxman, J.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group|1 1997
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063294/
https://www.ncbi.nlm.nih.gov/pubmed/9052419
_version_ 1782137306175504384
author Papamichael, D.
Gallagher, C. J.
Oliver, R. T.
Johnson, P. W.
Waxman, J.
author_facet Papamichael, D.
Gallagher, C. J.
Oliver, R. T.
Johnson, P. W.
Waxman, J.
author_sort Papamichael, D.
collection PubMed
description Fourteen patients with previously treated, locally advanced/metastatic transitional cell carcinoma (TCC) of the bladder or ureter received paclitaxel at a dose of 200 mg m-2 administered as a 3-h infusion every 21 days. The activity of paclitaxel in this group of patients was modest. The response rates were one partial response (PR) (7%) and three stable disease (SD). There were two early deaths.
format Text
id pubmed-2063294
institution National Center for Biotechnology Information
language English
publishDate 1997
publisher Nature Publishing Group|1
record_format MEDLINE/PubMed
spelling pubmed-20632942009-09-10 Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter. Papamichael, D. Gallagher, C. J. Oliver, R. T. Johnson, P. W. Waxman, J. Br J Cancer Research Article Fourteen patients with previously treated, locally advanced/metastatic transitional cell carcinoma (TCC) of the bladder or ureter received paclitaxel at a dose of 200 mg m-2 administered as a 3-h infusion every 21 days. The activity of paclitaxel in this group of patients was modest. The response rates were one partial response (PR) (7%) and three stable disease (SD). There were two early deaths. Nature Publishing Group|1 1997 /pmc/articles/PMC2063294/ /pubmed/9052419 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Papamichael, D.
Gallagher, C. J.
Oliver, R. T.
Johnson, P. W.
Waxman, J.
Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter.
title Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter.
title_full Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter.
title_fullStr Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter.
title_full_unstemmed Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter.
title_short Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter.
title_sort phase ii study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063294/
https://www.ncbi.nlm.nih.gov/pubmed/9052419
work_keys_str_mv AT papamichaeld phaseiistudyofpaclitaxelinpretreatedpatientswithlocallyadvancedmetastaticcancerofthebladderandureter
AT gallaghercj phaseiistudyofpaclitaxelinpretreatedpatientswithlocallyadvancedmetastaticcancerofthebladderandureter
AT oliverrt phaseiistudyofpaclitaxelinpretreatedpatientswithlocallyadvancedmetastaticcancerofthebladderandureter
AT johnsonpw phaseiistudyofpaclitaxelinpretreatedpatientswithlocallyadvancedmetastaticcancerofthebladderandureter
AT waxmanj phaseiistudyofpaclitaxelinpretreatedpatientswithlocallyadvancedmetastaticcancerofthebladderandureter

Ejemplares similares